

## SEQUENCE LISTING

*E*  
[ ]  
<110> Clinton, Gail M.  
Evans, Adam  
Henner, William D.

*D*  
<120> HER-2 BINDING ANTAGONISTS

<130> 49321-16

<140> US 09/506,079  
<141> 2000-02-16

<150> US 09/234,208  
<151> 1999-01-20

<160> 10

<210> 1  
<211> 79  
<212> PRT  
<213> Homo Sapiens

<220>  
<221> Variable  
<222> 2

<223> Applicants herein disclose Thr and Ser sequence variants at this position

<220>  
<221> Variable  
<222> 5

<223> Applicants herein disclose Leu and Pro sequence variants at this position

<220>  
<221> Variable  
<222> 6

<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>  
<221> Variable  
<222> 16

<223> Applicants herein disclose Leu and Gln sequence variants at this position

<220>  
<221> Variable  
<222> 18

<223> Applicants herein disclose Met and Leu sequence variants at this position

<220>  
<221> Variable  
<222> 21

<223> Applicants herein disclose Gly, Asp, Ala and Val sequence variants at this position

<220>  
<221> Variable  
<222> 36

<223> Applicants herein disclose Leu and Ile sequence variants at this position

<220>

<221> Variable

<222> 54

<223> Applicants herein disclose Pro and Arg sequence variants at this position

<220>

<221> Variable

<222> 64

<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>

<221> Variable

<222> 73

<223> Applicants herein disclose Asp and Asn sequence variants at this position

<400> 1

Gly Xaa His Ser Xaa Xaa Pro Arg Pro Ala Ala Val Pro Val Pro Xaa  
5 10 15

Arg Xaa Gln Pro Xaa Pro Ala His Pro Val Leu Ser Phe Leu Arg Pro  
20 25 30

Ser Trp Asp Xaa Val Ser Ala Phe Tyr Ser Leu Pro Leu Ala Pro Leu  
35 40 45

Ser Pro Thr Ser Val Xaa Ile Ser Pro Val Ser Val Gly Arg Gly Xaa  
50 55 60

Asp Pro Asp Ala His Val Ala Val Xaa Leu Ser Arg Tyr Glu Gly  
65 70 75

<210> 2

<211> 419

<212> PRT

<213> Homo Sapiens

<220>

<221> Variable

<222> 342

<223> Applicants herein disclose Thr and Ser sequence variants at this position

<220>

<221> Variable

<222> 345

<223> Applicants herein disclose Leu and Pro sequence variants at this position

<220>

<221> Variable

<222> 346

<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>

<221> Variable

<222> 356

<223> Applicants herein disclose Leu and Gln sequence variants at

this position  
<220>  
<221> Variable  
<222> 358  
<223> Applicants herein disclose Met and Leu sequence variants at this position  
<220>  
<221> Variable  
<222> 361  
<223> Applicants herein disclose Gly, Asp, Ala and Val sequence variants at this position  
<220>  
<221> Variable  
<222> 376  
<223> Applicants herein disclose Leu and Ile sequence variants at this position  
<220>  
<221> Variable  
<222> 394  
<223> Applicants herein disclose Pro and Arg sequence variants at this position  
<220>  
<221> Variable  
<222> 404  
<223> Applicants herein disclose Pro and Leu sequence variants at this position  
<220>  
<221> Variable  
<222> 413  
<223> Applicants herein disclose Asp and Asn sequence variants at this position

<400> 2  
Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu  
5 10 15  
Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Cys Lys  
20 25 30  
Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His  
35 40 45  
Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr  
50 55 60  
Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val  
65 70 75 80  
Gln Gly Tyr Val Leu Cys Ala His Asn Gln Val Arg Gln Val Pro Leu  
85 90 95  
Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr  
100 105 110  
Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Arg Arg Thr Thr Pro  
115 120 125  
Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser  
130 135 140  
Leu Thr Glu Cys Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln  
145 150 155 160  
Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn

165	170	175
Asn Gln Leu Ala Leu Thr Leu Ile Asp	Thr Asn Arg Ser Arg Ala Cys	
180	185	190
His Pro Cys Ser Pro Cys Cys Lys Gly Ser Arg Cys	Trp Gly Glu Ser	
195	200	205
Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val	Cys Ala Gly Gly Cys	
210	215	220
Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys	His Glu Gln Cys	
225	230	235
Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys	Leu Ala Cys Leu	
245	250	255
His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys	Pro Ala Leu Val	
260	265	270
Thr Tyr Asn Thr Asp Thr Phe Glu Ser Cys Pro Asn	Pro Glu Gly Arg	
275	280	285
Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys	Pro Tyr Asn Lys Leu	
290	295	300
Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys	Pro Leu His Asn Gln	
305	310	315
Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys	Glu Lys Cys Ser Lys	
325	330	335
Pro Cys Ala Arg Gly Xaa His Ser Xaa Xaa Pro Arg	Pro Ala Ala Val	
340	345	350
Pro Val Pro Xaa Arg Xaa Gln Pro Xaa Pro Ala His	Pro Val Leu Ser	
355	360	365
Phe Leu Arg Pro Ser Trp Asp Xaa Val Ser Ala	Phe Tyr Ser Leu Pro	
370	375	380
Leu Ala Pro Leu Asp Pro Thr Ser Val Xaa Ile	Ser Pro Val Ser Val	
385	390	395
Gly Arg Gly Xaa Asp Pro Asp Ala His Val Ala	Val Xaa Leu Ser Arg	
405	410	415
Tyr Glu Gly		

&lt;210&gt; 3

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER-2-specific oligonucleotide primer

&lt;400&gt; 3

tgagcaccat ggagctggc 19

&lt;210&gt; 4

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER-2-specific oligonucleotide primer

&lt;400&gt; 4

tccggcagaaa atgccaggct cc 22

&lt;210&gt; 5

<211> 22  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 cDNA-specific oligonucleotide primer

<400> 5  
aacacagcgg tgtgagaagt gc 22

<210> 6  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 ECDIIIa-region-specific oligonucleotide primer

<400> 6  
ataccgggac aggtcaacag c 21

<210> 7  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 ECDIIIa-region-specific oligonucleotide primer

<400> 7  
tctgggtacc cactcactgc 20

<210> 8  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 exon-specific oligonucleotide primer

<400> 8  
ttcacactgg cacgtccaga cc 22

<210> 9  
<211> 27  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 cDNA-specific oligonucleotide primer

<400> 9  
gcacggatcc atagcagact gaggagg 27

<210> 10  
<211> 240  
<212> DNA  
<213> Homo Sapiens  
<220>

<221> Variable

<222> 62

<223> Applicants disclose C, T, A and G variants at this position

<400> 10

ggt wcc cac tca cyg cyc ccg agg cca gct gca gtt cct gtc cct 45  
Gly Xaa His Ser Xaa Xaa Pro Arg Pro Ala Ala Val Pro Val Pro  
5 10 15

cwg cgc atr cag cct gnc cca gcc cac cct gtc cta tcc ttc ctc 90  
Xaa Arg Xaa Gln Pro Xaa Pro Ala His Pro Val Leu Ser Phe Leu  
20 25 30

aga ccc tct tgg gac mta gtc tct gcc ttc tac tct cta ccc ctg 135  
Arg Pro Ser Trp Asp Xaa Val Ser Ala Phe Tyr Ser Leu Pro Leu  
35 40 45

gcc ccc ctc agc cct aca agt gtc cst ata tcc cct gtc agt gtg 180  
Ala Pro Leu Ser Pro Thr Ser Val Xaa Ile Ser Pro Val Ser Val  
50 55 60

ggg agg ggc cyg gac cct gat gct cat gtg gct gtt sac ctg tcc 225  
Gly Arg Gly Xaa Asp Pro Asp Ala His Val Ala Val Xaa Leu Ser  
65 70 75

cgg tat gaa ggc tga 240  
Arg Tyr Glu Gly